BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 32173978)

  • 1. Role of common ERCC1 polymorphisms in cisplatin-resistant epithelial ovarian cancer patients: A study in Chinese cohort.
    Bao Y; Yang B; Zhao J; Shen S; Gao J
    Int J Immunogenet; 2020 Oct; 47(5):443-453. PubMed ID: 32173978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
    Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer.
    Moxley KM; Benbrook DM; Queimado L; Zuna RE; Thompson D; McCumber M; Premkumar P; Thavathiru E; Hines L; Moore KN
    Gynecol Oncol; 2013 Aug; 130(2):377-82. PubMed ID: 23632208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of ERCC1 polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer.
    Gao H; Ge RC; Liu HY; Wang Y; Yan S
    Genet Mol Res; 2014 Oct; 13(4):8997-9004. PubMed ID: 25366790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy.
    Mo J; Luo M; Cui J; Zhou S
    Int J Clin Exp Pathol; 2015; 8(11):15065-71. PubMed ID: 26823845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rs3212986 polymorphism, a possible biomarker to predict smoking-related lung cancer, alters DNA repair capacity via regulating ERCC1 expression.
    Yu T; Xue P; Cui S; Zhang L; Zhang G; Xiao M; Zheng X; Zhang Q; Cai Y; Jin C; Yang J; Wu S; Lu X
    Cancer Med; 2018 Dec; 7(12):6317-6330. PubMed ID: 30453383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphisms in ERCC1 gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients.
    Zhao X; Zhang Z; Yuan Y; Yuan X
    Tumour Biol; 2014 Aug; 35(8):8335-41. PubMed ID: 24859833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients.
    Takenaka T; Yano T; Kiyohara C; Miura N; Kouso H; Ohba T; Kometani T; Shoji F; Yoshino I; Maehara Y
    Lung Cancer; 2010 Jan; 67(1):101-7. PubMed ID: 19361884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of excision repair cross-complimentary group 1 gene polymorphisms with breast and ovarian cancer susceptibility.
    Yang F; Mu X; Bian C; Zhang H; Yi T; Zhao X; Lin X
    J Cell Biochem; 2019 Sep; 120(9):15635-15647. PubMed ID: 31081240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and Genetic Polymorphisms of ERCC1 in Chinese Han Patients with Oral Squamous Cell Carcinoma.
    Wang C; Gan N; Liu P; Chen H; Li Y; Li X
    Biomed Res Int; 2020; 2020():1207809. PubMed ID: 33029487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy.
    Lu ZM; Luo TH; Nie MM; Fang GE; Ma LY; Xue XC; Wei G; Ke CW; Bi JW
    Tumour Biol; 2014 Apr; 35(4):2941-8. PubMed ID: 24318989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic variability of ERCC1 genes in NER pathway influences the treatment outcome of gastric cancer.
    Bai Y; Wang L; Li G; Fang X; Li Y; Yang S
    Int J Clin Exp Pathol; 2015; 8(10):13367-73. PubMed ID: 26722542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphisms in ERCC1 and XPF gene and response to chemotherapy and overall survival of non-small cell lung cancer.
    Shi ZH; Shi GY; Liu LG
    Int J Clin Exp Pathol; 2015; 8(3):3132-7. PubMed ID: 26045829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association studies of ERCC1 polymorphisms with lung cancer susceptibility: a systematic review and meta-analysis.
    Zhu J; Hua RX; Jiang J; Zhao LQ; Sun X; Luan J; Lang Y; Sun Y; Shang K; Peng S; Ma J
    PLoS One; 2014; 9(5):e97616. PubMed ID: 24841208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ERCC1, XRCC1, and GSTP1 Polymorphisms and Treatment Outcomes of Advanced Epithelial Ovarian Cancer Patients Treated with Platinum-based Chemotherapy.
    Liblab S; Vusuratana A; Areepium N
    Asian Pac J Cancer Prev; 2020 Jul; 21(7):1925-1929. PubMed ID: 32711417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of excision repair cross-complementing group 1 genotypes to triple negative breast cancer risk.
    Tsai CW; Chang WS; Shen TC; Su CH; Wang HC; Liu LC; Bau DT
    PLoS One; 2018; 13(8):e0202112. PubMed ID: 30096175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study.
    Rubatt JM; Darcy KM; Tian C; Muggia F; Dhir R; Armstrong DK; Bookman MA; Niedernhofer LJ; Deloia J; Birrer M; Krivak TC
    Gynecol Oncol; 2012 May; 125(2):421-6. PubMed ID: 22261301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer.
    Krivak TC; Darcy KM; Tian C; Armstrong D; Baysal BE; Gallion H; Ambrosone CB; DeLoia JA;
    J Clin Oncol; 2008 Jul; 26(21):3598-606. PubMed ID: 18640939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy.
    Rumiato E; Cavallin F; Boldrin E; Cagol M; Alfieri R; Basso D; Castoro C; Ancona E; Amadori A; Ruol A; Saggioro D
    Pharmacogenet Genomics; 2013 Nov; 23(11):597-604. PubMed ID: 23962907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients.
    Park SR; Kong SY; Nam BH; Choi IJ; Kim CG; Lee JY; Cho SJ; Kim YW; Ryu KW; Lee JH; Rhee J; Park YI; Kim NK
    Br J Cancer; 2011 Mar; 104(7):1126-34. PubMed ID: 21364592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.